期刊文献+

小鼠端粒酶蛋白亚单位真核表达载体的构建和序列测定

Construction and identification of mouse telomerase reverse transcriptase eukaryotic expression vector
下载PDF
导出
摘要 目的:克隆小鼠端粒酶蛋白亚单位(mTERT)的cDNA,构建真核表达载体并进行序列测定。方法:从肝癌细胞中提取总RNA,采用RT-PCR技术扩增mTERT的基因编码区序列,将序列定向克隆至真核表达载体pAC,并进行序列测定。结果:获得mTERT编码区3 369 bp的cDNA片段,用PCR和限制性内切酶分析鉴定,表明获得重组质粒pAC-mTERT。通过对mTERT编码区cDNA序列测序证实其与GenBank中的已知序列一致。结论:成功克隆了mTERT编码区序列,并构建了其真核表达载体,为以TERT为基础的肿瘤生物治疗奠定基础。 AIM: To clone and express mouse telomerase reverse transcriptase (mTERT) cDNA and obtain eukaryotic expression vector. METHODS: The cDNA of mTERT was amplified by RT - PCR and PCR. After purification, the gene fragment was cloned into a vector PUC- 19. The sequence of inserted mTERT gene fragment was also detected. RESULTS: The recombi- nant plasmid PUC - 19 - mTERT was constructed. Positive clones were screened and identified by PCR and digestion with restriction enzyme. The size of gene fragment was 3 369 bp and in accordance with the expected one. CONCLUSION: The mTERT cDNA was obtained and the recombinant eukaryotic expression vector was successfully constructed. The study lays foundation for DCs vaccine modified by mTERT gene for the treatment of tumor.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2006年第5期851-855,共5页 Chinese Journal of Pathophysiology
基金 国家重点基础研究发展计划(973计划)课题(No.2003CB515507)
关键词 端粒 末端转移酶 寡核苷酸序列分析 真核表达载体 Telomerase Oligonucleotide army sequence analysis Eukaryotic expression vector
  • 相关文献

参考文献11

  • 1Poole JC, Andrews LG, Tollefsbol TO. Activity,function,and gene regulation of the catalytic subunit of telomerase (hTERT)[J]. Gene, 2001, 269(1-2): 1-12.
  • 2Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancers[J].Science, 1994, 266(5193) : 2011 - 2015.
  • 3Ducrest AL, Szutorisz H, Lingner J, et al. Regulation of the human telomerase reverse transcriptase gene [J]. Oncogene,2002, 21(4) : 541 - 552.
  • 4Harley CB. Telomerase is not an oncogene [J]. Oncogend,2002, 21(4) : 494 - 502.
  • 5Doyle LA, Highsmith WE. Telomerase as a diagnostic and therapeutic target for cancer[J]. Expert Rev Anticancer Ther,2002, 2(2) : 217- 225.
  • 6Takeuchi H, Kanzawa T, Kondo Y, et al. Combination of caspase transfer using the human telomerase reverse transcriptase promoter and conventional therapies for malignant glioma cells[J]. Int J Oncol, 2004, 25(1): 57-63.
  • 7Vonderheide Rh, Hahn WC, Schultze JL, et al. The telomerase catalytic subunit is a cidely expressed tumor- associated antigen recognized by cytotoxic T lymphocytes[J]. Immunity,1999, 10(6) : 673- 679.
  • 8Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide -based antitumor vaccines[J]. Stem Cells, 1997, 15(2): 94- 103.
  • 9Timmerman JM. Immunotherapy for lymphomas [J]. Int J Hematol, 2003, 77(5): 444-455.
  • 10Nestle FO, Farkas A, Conrad C. Dendritic - cell- based therapeutic vaccination against cancer [J]. Curt Opin Immunol, 2005, 17(2). 163 - 169.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部